Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma

Table 3

Hazard ratios of cell expression for mortality risk.

Variables	Univariate model			Multiple model
	Adjusted HR	95% CI	value	Adjusted HR	95% CI	value
ER cytosolic						<0.001
Weak	1			1
Strong (≧6)	0.38	0.16–0.87	0.023	0.23	0.07–0.76	0.015
Age	1.07	1.03–1.11	0.001	1.06	1.01–1.11	0.010
Gender
Female	1			1
Male	2.17	1.07–4.40	0.031	8.77	2.02–38.00	0.004

Adjusted HR, adjusted hazard ratio; 95% CI, 95% confidence interval.